WO2002028363A1 - Eye instillation with decongestant effect - Google Patents

Eye instillation with decongestant effect Download PDF

Info

Publication number
WO2002028363A1
WO2002028363A1 PCT/SK2001/000019 SK0100019W WO0228363A1 WO 2002028363 A1 WO2002028363 A1 WO 2002028363A1 SK 0100019 W SK0100019 W SK 0100019W WO 0228363 A1 WO0228363 A1 WO 0228363A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
medium
range
auxiliary substances
keep
Prior art date
Application number
PCT/SK2001/000019
Other languages
French (fr)
Inventor
Vladimír JANCUS
Jozef AMBRÓ
Elena SLUCIAKOVÁ
Original Assignee
Unimed Pharma Spol S.R.O.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unimed Pharma Spol S.R.O. filed Critical Unimed Pharma Spol S.R.O.
Priority to AU2001269672A priority Critical patent/AU2001269672A1/en
Publication of WO2002028363A1 publication Critical patent/WO2002028363A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Definitions

  • Present technical solution relates to eye instillation with decongestant effect, based on a sympathomimetic, a substance for decongestion of the front eye segment, combined with a bioflavonoid.
  • the group of known ophthalmological preparations showing vasoconstrictive effect is now complemented with an eye instillation according to the present technical solution, the nature of which consists in that it contains from 0.001 % to 1 % by weight of tetrahydrozoline hydrochloride (vasoconstrictor, decongestant) and from 0.001 % to 1 % by weight of rutin trihydrate (bioflavonoid) or possibly its sulfate salt with sulfuric acid, further from 0.0005 to 0.1 % by weight of a preserving additive, from 0.01 to 2 % by weight of auxiliary substances which help to keep the pH value of the medium within a range from 5 to 8.0, from 0.01 to 5 % by weight of auxiliary substances which keep viscosity of the medium within a range of 5 to 25 mPa.s, and the rest to 100 % by weight consists of distilled water.
  • tetrahydrozoline hydrochloride vasoconstrictor, decongestant
  • the auxiliary substances which keep the pH value of the medium within a range from 5 to 8.0 include sodium acetate, sodium chloride, boric acid, borax, disodium edetate, sodium hydrogen phosphate or sodium dihydrogen phosphate, alone or in a mixture.
  • the auxiliary substances which keep viscosity of the medium within a range of 5 to 25 mPa.s include hydroxypropylmethylcellulose and polyoxyethylenesorbitan monooleate, alone or in a mixture.
  • the preserving additive is benzalkonium chloride, carbetopendecinium bromide, thimerosal, chlorohexidine or chlorobutanol.
  • the active substance tetrahydrozoline hydrochloride is an alpha- sympathomimetic which is a derivative of adrenergens of the imidazoline group.
  • the second active substance of the preparation is rutin trihydrate. Rutin is a bioflavonoid which is important for normal functioning of capillaries.
  • the preparation shows also a moderate antiallergenic effect. It diminishes allergic manifestations of the eye caused by allergens.
  • An advantage of the instillation according to the present solution is an increased efficiency in treating oedematous and hyperaemic conditions of conjunctiva, caused by smoking, dust, wind, chlorinated water, sun, neon light, electrical welding, cosmetic preparations or contact lens, as well as elimination of allergic itises such as nasal allergy and hypersensitiveness to pollen. It affects secondarily the local signs of bleeding at diabetic retinopathy.
  • the amounts of components of a production batch are a linear function of the amounts per one package, i. e. 10 ml.
  • composition for one package tetrahydrozoline hydrochloride 0.00010 g rutin trihydrate 0.00010 g sodium chloride 0.00100 g boric acid 0.00100 g borax 0.00100 g disodium edetate 0.00100 g benzalkonium chloride 0.00005 g sterilized distilled water ad 10 ml
  • composition for one package tetrahydrozoline hydrochloride 0.00010 g rutin trihydrate 0.00010 g sodium acetate 0.01000 g boric acid 0.01000 g disodium edetate 0.00010 g tween 80 0.00100 g hypromellose 0.00100 g thimerosal 0.00005 g sterilized distilled water ad 10 ml
  • composition for one package tetrahydrozoline hydrochloride 0.00010 g rutin trihydrate 0.00010 g sodium chloride 0.00100 g chlorohexidine 0.00005 g sterilized distilled water ad 10 ml
  • composition for one package tetrahydrozoline hydrochloride 0.00010 g rutin trihydrate 0.00010 g sodium hydrogen phosphate 0.01000 g sodium dihydrogen phosphate 0.01000 g hypromellose 0.00100 g chlorobutanol 0.00005 g sterilized distilled water ad 10 ml e) Composition for one package: tetrahydrozoline hydrochloride 0.00010 g rutin trihydrate 0.00010 g boric acid 0.01000 g disodium edetate 0.00010 g carbetopendecinium bromide 0.00005 g sterilized distilled water ad 10 ml
  • composition for one package tetrahydrozoline hydrochloride 0.00010 g rutin trihydrate 0.00010 g sodium hydrogen phosphate 0.01000 g benzalkonium chloride 0.00005 g sterilized distilled water ad 10 ml
  • the amounts of components of a production batch are a linear function of the amounts per one package, i. e. 10 ml.
  • composition for one package tetrahydrozoline hydrochloride 0.10000 g rutin trihydrate 0.10000 g sodium chloride 0.20000 g boric acid 0.20000 g borax 0.20000 g disodium edetate 0.20000 g benzalkonium chloride 0.01000 g sterilized distilled water ad 10 ml
  • Composition for one package tetrahydrozoline hydrochloride 0.10000 g rutin trihydrate 0.10000 g sodium acetate 0.20000 g boric acid 0.20000 g disodium edetate 0.20000 g tween 80 0.50000 g hypromellose 0.50000 g thimerosal 0.01000 g sterilized distilled water ad 10 ml
  • composition for one package tetrahydrozoline hydrochloride 0.10000 g rutin trihydrate 0.10000 g disodium chloride 0.20000 g chlorohexidine 0.01000 g sterilized distilled water ad 10 ml
  • composition for one package tetrahydrozoline hydrochloride 0.10000 g rutin trihydrate 0.10000 g sodium hydrogen phosphate 0.20000 g sodium dihydrogen phosphate 0.20000 g hypromellose 0.50000 g chlorobutanol 0.01000 g sterilized distilled water ad 10 ml
  • composition for one package tetrahydrozoline hydrochloride 0.10000 g rutin trihydrate 0.10000 g boric acid 0.20000 g disodium edetate 0.20000 g carbetopendecinium bromide 0.01000 g sterilized distilled water ad 10 ml
  • composition for one package tetrahydrozoline hydrochloride 0.10000 g rutin trihydrate 0.10000 g sodium hydrogen phosphate 0.20000 g benzalkonium chloride 0.01000 g sterilized distilled water ad 10 ml Industrial applicability
  • the eye instillation according to the present technical solution can be utilized in ophthalmology in treating oedematous and hyperaemic conditions of conjunctiva, secondarily to affect the local signs of bleeding at diabetic retinopathy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Eye instillation with decongestant effect contained from 0.001 to 1% by weight of tetrahydrozoline hydrochloride, from 0.001 to 1% by weight of rutin trigydrate or its sulfate salt as the active substance, further from 0.0005 to 0.1% by weight of a preserving additive, from 0.01 to 2% by weight of auxiliary substances which keep the pH value of the medium within a range from 5 to 8.0, from 0.01 to 5% by weight of auxiliary substances which keep viscosity of the medium within a range of 5 to 25 mPa.s, and the rest to 100% by weight consists of distilled water.

Description

Eye instillation with decongestant effect
Technical Field
Present technical solution relates to eye instillation with decongestant effect, based on a sympathomimetic, a substance for decongestion of the front eye segment, combined with a bioflavonoid.
Background Art
In ophthalmological practice, several individual as well as combined preparations based on a sympathomimetic or a sympathomimetic with synergically acting substances are used: Visin (tetrahydrozoline), Nasopos Ν (tetrahydrozoline), Oculosan Ν (naphazoline, zinc sulfate).
Preparations based on a sympathomimetic combined with a bioflavonoid, substances supporting the correct functioning of capillaries, have not been known yet.
Description of Technical Solution
The group of known ophthalmological preparations showing vasoconstrictive effect is now complemented with an eye instillation according to the present technical solution, the nature of which consists in that it contains from 0.001 % to 1 % by weight of tetrahydrozoline hydrochloride (vasoconstrictor, decongestant) and from 0.001 % to 1 % by weight of rutin trihydrate (bioflavonoid) or possibly its sulfate salt with sulfuric acid, further from 0.0005 to 0.1 % by weight of a preserving additive, from 0.01 to 2 % by weight of auxiliary substances which help to keep the pH value of the medium within a range from 5 to 8.0, from 0.01 to 5 % by weight of auxiliary substances which keep viscosity of the medium within a range of 5 to 25 mPa.s, and the rest to 100 % by weight consists of distilled water.
The auxiliary substances which keep the pH value of the medium within a range from 5 to 8.0, include sodium acetate, sodium chloride, boric acid, borax, disodium edetate, sodium hydrogen phosphate or sodium dihydrogen phosphate, alone or in a mixture. The auxiliary substances which keep viscosity of the medium within a range of 5 to 25 mPa.s, include hydroxypropylmethylcellulose and polyoxyethylenesorbitan monooleate, alone or in a mixture.
The preserving additive is benzalkonium chloride, carbetopendecinium bromide, thimerosal, chlorohexidine or chlorobutanol.
The active substance tetrahydrozoline hydrochloride is an alpha- sympathomimetic which is a derivative of adrenergens of the imidazoline group. The second active substance of the preparation is rutin trihydrate. Rutin is a bioflavonoid which is important for normal functioning of capillaries.
After an application of the instillation according to the present solution to the pacients conjunctival sac an increased anti-inflammatory and anti-oedematous effect arises as a result of modification of an increased refraction and increased permeability of capillaries in an interaction with vessel vasoconstriction. Generally, microcirculation is improved and subjective compliants are diminished.
The preparation shows also a moderate antiallergenic effect. It diminishes allergic manifestations of the eye caused by allergens.
An advantage of the instillation according to the present solution is an increased efficiency in treating oedematous and hyperaemic conditions of conjunctiva, caused by smoking, dust, wind, chlorinated water, sun, neon light, electrical welding, cosmetic preparations or contact lens, as well as elimination of allergic itises such as nasal allergy and hypersensitiveness to pollen. It affects secondarily the local signs of bleeding at diabetic retinopathy.
Examples of embodiments
Example 1
Weighed amounts of components (according to the production batch size) are dissolved in sterilized distilled water under aseptic conditions. After having dissolved them sterilized distilled water is added to the solution up to the specified volume. The resulting, solution is sterilized by filtration through a membrane filter with 0.2 μm mesh and immediately dosed into sterile vials under aseptic conditions and sealed with sterile seals. The sealed vials are labeled and packed into specified packages.
The amounts of components of a production batch are a linear function of the amounts per one package, i. e. 10 ml.
a) Composition for one package: tetrahydrozoline hydrochloride 0.00010 g rutin trihydrate 0.00010 g sodium chloride 0.00100 g boric acid 0.00100 g borax 0.00100 g disodium edetate 0.00100 g benzalkonium chloride 0.00005 g sterilized distilled water ad 10 ml
b) Composition for one package: tetrahydrozoline hydrochloride 0.00010 g rutin trihydrate 0.00010 g sodium acetate 0.01000 g boric acid 0.01000 g disodium edetate 0.00010 g tween 80 0.00100 g hypromellose 0.00100 g thimerosal 0.00005 g sterilized distilled water ad 10 ml
c) Composition for one package: tetrahydrozoline hydrochloride 0.00010 g rutin trihydrate 0.00010 g sodium chloride 0.00100 g chlorohexidine 0.00005 g sterilized distilled water ad 10 ml
d) Composition for one package: tetrahydrozoline hydrochloride 0.00010 g rutin trihydrate 0.00010 g sodium hydrogen phosphate 0.01000 g sodium dihydrogen phosphate 0.01000 g hypromellose 0.00100 g chlorobutanol 0.00005 g sterilized distilled water ad 10 ml e) Composition for one package: tetrahydrozoline hydrochloride 0.00010 g rutin trihydrate 0.00010 g boric acid 0.01000 g disodium edetate 0.00010 g carbetopendecinium bromide 0.00005 g sterilized distilled water ad 10 ml
f) Composition for one package: tetrahydrozoline hydrochloride 0.00010 g rutin trihydrate 0.00010 g sodium hydrogen phosphate 0.01000 g benzalkonium chloride 0.00005 g sterilized distilled water ad 10 ml
Example 2
Weighed amounts of components (according to the production batch size) are dissolved in sterilized distilled water under aseptic conditions. After having dissolved them sterilized distilled water is added to the solution up to the specified volume. The resulting solution is sterilized by filtration through a membrane filter with 0.2 μm mesh and immediately dosed into sterile vials under aseptic conditions and sealed with sterile seals. The sealed vials are labeled and packed into specified packages.
The amounts of components of a production batch are a linear function of the amounts per one package, i. e. 10 ml.
a) Composition for one package: tetrahydrozoline hydrochloride 0.10000 g rutin trihydrate 0.10000 g sodium chloride 0.20000 g boric acid 0.20000 g borax 0.20000 g disodium edetate 0.20000 g benzalkonium chloride 0.01000 g sterilized distilled water ad 10 ml b) Composition for one package: tetrahydrozoline hydrochloride 0.10000 g rutin trihydrate 0.10000 g sodium acetate 0.20000 g boric acid 0.20000 g disodium edetate 0.20000 g tween 80 0.50000 g hypromellose 0.50000 g thimerosal 0.01000 g sterilized distilled water ad 10 ml
c) Composition for one package: tetrahydrozoline hydrochloride 0.10000 g rutin trihydrate 0.10000 g disodium chloride 0.20000 g chlorohexidine 0.01000 g sterilized distilled water ad 10 ml
d) Composition for one package: tetrahydrozoline hydrochloride 0.10000 g rutin trihydrate 0.10000 g sodium hydrogen phosphate 0.20000 g sodium dihydrogen phosphate 0.20000 g hypromellose 0.50000 g chlorobutanol 0.01000 g sterilized distilled water ad 10 ml
e) Composition for one package: tetrahydrozoline hydrochloride 0.10000 g rutin trihydrate 0.10000 g boric acid 0.20000 g disodium edetate 0.20000 g carbetopendecinium bromide 0.01000 g sterilized distilled water ad 10 ml
f) Composition for one package: tetrahydrozoline hydrochloride 0.10000 g rutin trihydrate 0.10000 g sodium hydrogen phosphate 0.20000 g benzalkonium chloride 0.01000 g sterilized distilled water ad 10 ml Industrial applicability
The eye instillation according to the present technical solution can be utilized in ophthalmology in treating oedematous and hyperaemic conditions of conjunctiva, secondarily to affect the local signs of bleeding at diabetic retinopathy.

Claims

PROTECTION CLAIMS
1. Eye instillation with decongestant effect, characterized in that it contains from 0.001 to 1 % by weight of tetrahydrozoline hydrochloride, from 0.001 to 1 % by weight of rutin trihydrate or its sulfate salt as the active substance, further from 0.0005 to 0.1 % by weight of a preserving additive, from 0.01 to 2 % by weight of auxiliary substances which keep the pH value of the medium within a range from 5 to 8.0, from 0.01 to 5 % by weight of auxiliary substances which keep viscosity of the medium within a range of 5 to 25 mPa.s, and the rest to 100 % by weight consists of distilled water.
2. Eye instillation according to claim 1, characterized in that the preserving additive is benzalkonium chloride, carbetopendecinium bromide, thimerosal, chlorohexidine or chlorobutanol.
3. Eye instillation according to claims 1 and 2, characterized in that the auxiliary substances which keep the pH value of the medium within a range from 5 to 8.0, include sodium acetate, sodium chloride, boric acid, borax, disodium edetate, sodium hydrogen phosphate or sodium dihydrogen phosphate, alone or in a mixture.
4. Eye instillation according to claims 1, 2 and 3, ch ar act er i ze d in that the auxiliary substances which keep viscosity of the medium within a range of 5 to 25 mPa.s, include hydroxypropylmethylcellulose and polyoxyethylenesorbitan monooleate, alone or in a mixture.
PCT/SK2001/000019 2000-10-05 2001-07-09 Eye instillation with decongestant effect WO2002028363A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001269672A AU2001269672A1 (en) 2000-10-05 2001-07-09 Eye instillation with decongestant effect

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SK3092000 2000-10-05
SKPÚV0309-2000 2000-10-05

Publications (1)

Publication Number Publication Date
WO2002028363A1 true WO2002028363A1 (en) 2002-04-11

Family

ID=20435801

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SK2001/000019 WO2002028363A1 (en) 2000-10-05 2001-07-09 Eye instillation with decongestant effect

Country Status (3)

Country Link
AU (1) AU2001269672A1 (en)
FR (1) FR2814955B3 (en)
WO (1) WO2002028363A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090712A2 (en) * 2002-04-26 2003-11-06 Allergan, Inc. Compositions for treating hyperemia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0420232A2 (en) * 1989-09-28 1991-04-03 EUROPEAN PHARMACY Srl Water soluble derivatives of glycoside bioflavonoids, processes for their preparation and related pharmaceutical compositions
WO1999004823A1 (en) * 1997-07-23 1999-02-04 Farmigea S.P.A. Process for solubilizing pharmaceutically active ingredients in water and in aqueous vehicles
EP0903151A1 (en) * 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0420232A2 (en) * 1989-09-28 1991-04-03 EUROPEAN PHARMACY Srl Water soluble derivatives of glycoside bioflavonoids, processes for their preparation and related pharmaceutical compositions
WO1999004823A1 (en) * 1997-07-23 1999-02-04 Farmigea S.P.A. Process for solubilizing pharmaceutically active ingredients in water and in aqueous vehicles
EP0903151A1 (en) * 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090712A2 (en) * 2002-04-26 2003-11-06 Allergan, Inc. Compositions for treating hyperemia
WO2003090712A3 (en) * 2002-04-26 2004-02-26 Allergan Inc Compositions for treating hyperemia
US6982079B2 (en) 2002-04-26 2006-01-03 Allergan, Inc. Compositions for treating hyperemia

Also Published As

Publication number Publication date
FR2814955B3 (en) 2002-11-15
FR2814955A1 (en) 2002-04-12
AU2001269672A1 (en) 2002-04-15

Similar Documents

Publication Publication Date Title
CN101405009B (en) Ophthalmic composition comprising xanthan gum and glucose
US4136178A (en) Locust bean gum therapeutic compositions
US5945121A (en) Liposome eye drops
AU742920B2 (en) Autoclavable pharmaceutical compositions containing a chelating agent
ES2204879T5 (en) NEUROPROTECTOR FOR THE EYE OF MAMMALS THROUGH ADMINISTRATION OF BLOCKERS OF THE POTASSIUM CHANNEL.
AU784017B2 (en) Solutions containing epinastine
JP5201795B2 (en) Pruritus inhibitor
KR101322527B1 (en) Eye drop preparation comprising xanthan gum and terpenoid
JP2824863B2 (en) α ▲ Lower 1 ▼ -Blocker eye drops
CN112791113A (en) Blueberry and lutein eye drops for relieving eye fatigue and preparation method thereof
EP1278511B1 (en) Use of a lacrophyl preparation in eye-drops containing therapeutically active compounds
US4197301A (en) Topical ophthalmic use of Prazosin
EP0048023A2 (en) Composition for treating and preventing irritation of the eyes
CN101031310B (en) Ophthalmic composition containing xanthan gum and amino acid
KR20030001490A (en) Ophthalmic solution
WO2002028363A1 (en) Eye instillation with decongestant effect
EP0069075B1 (en) Pharmaceutical preparation for treating glaucoma and ocular hypertension
JP2003073303A (en) Method for maintaining refreshing activity of eye drops
CN101765612A (en) complexes of prostaglandin derivatives and monosubstituted, charged beta-cyclodextrins
KR102444571B1 (en) Opthalmic compositions comprising cetirizine and tocofersolan
JPH05221873A (en) Pharmaceutical composition containing bradykinin antagonist for local use in nose and eye
ITMI971341A1 (en) TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING PYRPHENOXONE AND USE OF THE SAME IN THE TREATMENT OF INFLAMMATORY CONDITIONS
US5457126A (en) Use of lodoxamide to treat ophthalmic allergic conditions
EP0719553A1 (en) Pharmaceutical composition for topical administration to the eye for treating allergic conjunctivitis
JPH0778022B2 (en) Glaucoma treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RU SD SE SG SI SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RU SD SE SG SI SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP